Singapore and Indonesia Strengthen Regulatory Cooperation with New MoU

On 15 January 2026, the Health Sciences Authority (HSA) of Singapore and the Indonesian Food and Drug Authority (BPOM) signed a Memorandum of Understanding (MoU) to strengthen bilateral regulatory cooperation in the oversight of pharmaceuticals and health products. The signing took place in Jakarta, representing a meaningful step forward in the regional coordination of regulatory activities and public health protection.

Both regulatory authorities bring significant experience to this collaboration, having achieved World Health Organisation Listed Authority (WLA) status, recognising that their regulatory systems meet high international standards. This shared foundation of regulatory maturity provides fertile ground for deeper cooperation aimed at enhancing public health outcomes across both countries.

Scope of the Regulatory Cooperation

The MoU establishes a strategic framework for collaboration across a broad range of regulatory functions. Key areas of focus include:

• Exchange of regulatory information and best practices to support timely and informed decision-making across regulatory portfolios.

• Joint assessment of medicines and complementary health products, which can facilitate harmonised evaluation approaches.

• Strengthening of clinical trial oversight, ensuring consistent standards for design, conduct, and safety monitoring.

• Capacity building initiatives, including staff training programmes and collaborative workshops, to uplift regulatory competencies in both agencies.

• Cooperation in emerging regulatory fields, such as the integration of artificial intelligence into regulatory surveillance and scientific assessment processes.

These areas reflect a forward-thinking approach to regulatory collaboration and align with international trends in strengthening regulatory systems through shared expertise and coordinated oversight.

Why This Matters for the Region

This MoU is significant for several reasons. First, it demonstrates a shared commitment to regulatory excellence and confidence in each authority’s regulatory maturity. Both HSA and BPOM are recognised as WLAs by the World Health Organisation, underscoring their capacity to meet global standards in regulatory oversight.

Second, joint regulatory efforts can help enhance public health protection by enabling quicker access to reliable safety and quality information, especially for high-impact health products and emerging technologies. Enhanced cooperation on clinical trial supervision and joint product assessments also creates clearer pathways for developers and manufacturers operating in both markets.

Third, the partnership reflects a broader regional aspiration toward regulatory harmonisation within ASEAN. By working together, HSA and BPOM contribute to building more resilient and aligned regulatory ecosystems, which can, in turn, support improved patient outcomes and more efficient regulatory processes across the region.

Industry and Regulatory Implications

For pharmaceutical and health product stakeholders, this MoU can have several practical implications:

• Streamlined regulatory communication and potential alignment of expectations in dossier requirements and evaluation criteria between Singapore and Indonesia.

• Opportunities for collaborative work on high-priority health products, including advanced therapies and technologies that may benefit from coordinated approaches.

• Enhanced capacity building through shared programmes, workshops, and training that strengthen the regulatory workforce in both jurisdictions.

• Improved readiness for emerging regulatory challenges, particularly where advanced technologies and data-driven tools, including AI, play an increasing role in product development and oversight.

As regulatory systems continue to modernise and harmonise globally, strategic bilateral collaborations such as this MoU help create a more predictable and cooperative regulatory environment, an outcome that benefits regulators, industry, and ultimately, patients.

Looking Ahead

The Singapore–Indonesia MoU represents a milestone in ASEAN regulatory cooperation and sets a precedent for deeper collaboration in the oversight of medicines, health products, and emerging technologies. As both HSA and BPOM work together under this framework, stakeholders should watch for concrete outputs such as joint assessment initiatives, capacity building programmes, and aligned regulatory guidance that may result from this partnership.

Overall, this development underscores a shared vision of regulatory excellence and regional integration in regulatory practice that supports safe, effective, and innovative health solutions for populations in both countries.

Source:

HSA Signs Memorandum of Understanding with The Indonesian Food and Drug Authority to Strengthen Regulatory Cooperation on Medicines and Complementary Health Products. Health Sciences Authority (HSA), 15 January 2026.